COMMUNIQUÉS West-GlobeNewswire

ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors
06/08/2025
Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific. Buchanan, formerly a venture capitalist with the [...]
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
06/08/2025
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted [...]
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
06/08/2025
Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition strengthens Sanofi’s early- [...]
Communiqué de presse : Sanofi finalise l’acquisition de Vigil Neuroscience, Inc.
06/08/2025
Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Paris, le 6 août 2025. Sanofi annonce la finalisation de l’acquisition de Vigil Neuroscience, Inc. (« Vigil »). Cette acquisition renforce le pipeline de Sanofi [...]
BriaCell Announces Proposed Effective Date of Share Consolidation
06/08/2025
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotechnology [...]
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
06/08/2025
Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address [...]
Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform
06/08/2025
HOUSTON and SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced [...]
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
06/08/2025
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations
06/08/2025
DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations [...]
BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
05/08/2025
MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based [...]
Galecto Reports Second Quarter 2025 Operating and Financial Results
05/08/2025
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and [...]
Fractyl Health Announces Proposed Public Offering
05/08/2025
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches that treat root causes of [...]
Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
05/08/2025
JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value [...]
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update
05/08/2025
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 6 3% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - Based on the [...]
Supernus Announces Second Quarter 2025 Financial Results
05/08/2025
Net sales of Qelbree ® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, [...]
LeMaitre Q2 2025 Financial Results
05/08/2025
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0. [...]
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
05/08/2025
CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi [...]
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
05/08/2025
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
05/08/2025
Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with type 2 diabetes (T2D) not achieving glycemic targets, icovamenib [...]

Pages